BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

F2G Ltd and the University of Manchester Announce a New €6.1 Million Project to Develop New Antifungal Agents to Treat Resistant Fungal Infections


6/25/2013 10:14:17 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Manchester UK, 25th June 2013 -- F2G Ltd, a privately-held antifungal drug discovery and development company and The University of Manchester, today announced the commencement of a 6.1 million euro EU-funded project to discover and develop novel antifungal drugs to treat serious, lifethreatening fungal infections. The NOFUN project is a collaborative project under the 7th Framework Program of the European Commission which brings together five partners to accelerate the development of a number of F2G’s broad spectrum antifungal agents.

About two million people die each year because of fungal infection and resistance is rapidly emerging to the most common drugs used to treat these diseases. This project aims to develop novel agents with completely new ways of acting in order to combat the increasing tide of drug resistant fungal infections. NOFUN will use F2G’s discovery assets and the University’s fungal genomics platforms in addition to the drug development and characterisation expertise of the other partners.

Participants in the NOFUN Project are F2G Ltd (UK), The University of Manchester (UK), Pharmacelsus GmbH (Germany), OncoTargeting AB (Sweden) and Universitat i Rovira Virgili (Spain).

Dr Mike Birch of F2G and Scientific Coordinator of NOFUN added: “Competition for funding in this call was immense and the NOFUN award represents a significant validation of the project and the partners. F2G is delighted to lead the scientific program to develop much needed new antifungal agents”.

Dr Mike Bromley, NOFUN Project Coordinator from The Manchester Fungal Infection Group at The University of Manchester, said: “We are delighted that this project has been funded and it confirms The University of Manchester as a centre of excellence in fungal biology and disease. Hopefully this cash boost will help us to create new treatments to tackle serious, life-threatening fungal infections.”

About F2G Ltd: Based in Manchester, UK, F2G Ltd is dedicated to the discovery and development of new and clinically superior drug classes to treat life-threatening systemic fungal infections in at-risk patient populations. This is a growing health risk for which there are currently limited treatment options and for which demand is increasing globally. Market growth is expected to increase with the emergence of new clinical indications in allergies and asthma. For more information visit www.f2g.com

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES